Table 2 Survival of patients with MF who received upfront HCT vs. JAKi in DIPSS-stratified categories.

From: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study

 

36-month survival, median (95% CI)

60-month survival, median (95% CI)

 

JAKi

HCT

P value

JAKi

HCT

P value

Total cohort (n = 302)

0.69 (0.63-0.76)

0.53 (0.43-0.65)

0.01

0.56 (0.48-0.65)

0.50 (0.48-0.65)

0.41

Int-1 (n = 126)

0.79 (0.71-0.89)

0.57 (0.40-0.80)

0.04

0.68 (0.57-0.80)

0.57 (0.40-0.80)

0.34

Int-2, High (n = 176)

0.60 (0.35-0.62)

0.51 (0.40-0.71)

0.28

0.43 (0.31-0.58)

0.46 (0.35-0.62)

1.00

  1. MF myelofibrosis, JAKi JAK inhibitor therapy, HCT allogeneic hematopoietic cell transplantation, PMF primary myelofibrosis, DIPSS dynamic international prognostic scoring system, CI Confidence interval.
Back to article page